Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors

Trial Profile

Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs JS 001 (Primary)
  • Indications Cholangiocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shanghai Junshi Biosciences
  • Most Recent Events

    • 27 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
    • 12 Sep 2017 Enrollment for this study was completed by October 2016, according to results presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top